1. Home
  2. KMDA vs BGB Comparison

KMDA vs BGB Comparison

Compare KMDA & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kamada Ltd.

KMDA

Kamada Ltd.

SELL

Current Price

$8.15

Market Cap

460.3M

Sector

Health Care

ML Signal

SELL

Logo Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

BGB

Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

SELL

Current Price

$11.08

Market Cap

488.8M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
KMDA
BGB
Founded
1990
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
460.3M
488.8M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
KMDA
BGB
Price
$8.15
$11.08
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $13.75
N/A
AVG Volume (30 Days)
103.5K
★ 168.2K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
6.86%
★ 9.75%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.75
N/A
Revenue Next Year
$13.63
N/A
P/E Ratio
$24.59
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$10.85
52 Week High
$9.35
$12.01

Technical Indicators

Market Signals
Indicator
KMDA
BGB
Relative Strength Index (RSI) 56.89 48.03
Support Level $7.99 $10.98
Resistance Level $8.62 $11.21
Average True Range (ATR) 0.25 0.08
MACD 0.09 0.00
Stochastic Oscillator 88.61 34.21

Price Performance

Historical Comparison
KMDA
BGB

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.

Share on Social Networks: